

Application No.: 09/391,606

2

Amendments to the Claims:

1. (Currently amended) An immunogenic composition for ~~in vivo administration to a~~ host, comprising:

- a first plasmid vector comprising:

- a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of *Chlamydia pneumoniae*, said first nucleotide sequence being selected from those having SEQ ID Nos: 12, 13, or 14, 15 and 16, and

- a first promoter sequence operatively coupled to said first nucleotide sequence for expression of said MOMP in a the host;

- a second plasmid vector comprising:

- a second nucleotide sequence encoding a 76 kDa protein of a strain of *Chlamydia pneumoniae*, said second nucleotide sequence being selected from those having SEQ ID Nos: 1, 2, 3, or 4, and a
  - second promoter sequence operatively coupled to said second nucleotide sequence for expression of said 76 kDa protein in a the host; and

- a pharmaceutically-acceptable carrier therefor.

2. (Cancelled)

3. (Withdrawn)

4. and 5. (Cancelled)

6. (Currently amended) The immunogenic composition of claim 1 ~~2~~ wherein the first promoter is a cytomegalovirus promoter.

7. (Cancelled)

8. (Withdrawn)

9. (Cancelled)

Application No.: 09/391,606

3

10. (Currently amended) The immunogenic composition of claim 1 ~~7~~ wherein said second nucleotide sequence encodes the 76 kDa protein having a molecular size of about 35 kDa and having SEQ ID No: 7.

11. (Currently amended) The immunogenic composition of claim 1 ~~7~~ wherein said second nucleotide sequence encodes the 76 kDa protein having a molecular size of about 60 kDa and having SEQ ID No: 8 or 9.

12. (Currently amended) The immunogenic composition of claim 1 ~~7~~ wherein said second promoter is a cytomegalovirus promoter.

13. to 17 (Cancelled)

18. (Currently amended) The immunogenic composition of claim 1 ~~17~~ wherein said first plasmid vector is pCAMOMP and said second plasmid vector is pCA76kDa.

19. (Original) The immunogenic composition of claim 1 wherein said first and second vectors are present in amounts such that the individual protective effect of each vector upon administration of the composition to the host is not adversely affected by the other.

20. (Original) The immunogenic composition of claim 1 wherein said first and second vectors are present in amounts such that an enhanced protective effect is achieved in comparison to the individual vectors alone.

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)